Study of Phosphate Levels in Patients With Chronic Kidney Disease

Phase 2 Completed 154 enrolled Vifor Pharma

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.

Timeline

Start: 2008-12
Primary completion: 2009-10
Completion: 2010-03

Publications

Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PA21	Unknown	1.25 g	Oral
Subject	PA21	Unknown	5 g	Oral
Subject	PA21	Unknown	7.5 g	Oral
Subject	PA21	Unknown	10 g	Oral
Subject	PA21	Unknown	12.5 g	Oral
Subject	Sevelamer	Other / unclassified	4.8 g	Oral

Study of Phosphate Levels in Patients With Chronic Kidney Disease

Summary

Timeline

Publications

Drugs

Indications